Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Islet Sciences gets rights to remogliflozin from BHV

Executive Summary

BHV Pharma Inc. (Brighthaven Ventures) licensed Islet Sciences Inc. exclusive worldwide rights--excluding Japan, Korea, Taiwan, China, and Latin America--to develop and commercialize its Phase IIb SGLT2 inhibitor remogliflozin etabonate for Type II diabetes and nonalcoholic steatohepatitis (NASH).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies